FDA Expands Approval of Drug to Stave Off Type 1 Diabetes

(MedPage Today) -- The FDA expanded the approval for teplizumab (Tzield), a biologic that delays the progression of preclinical type 1 diabetes to the symptomatic form, to include treatment in kids as young as 1 year, Sanofi announced on Wednesday...
Source
MedPage Today
Opens original article in a new tab



